Patented small molecules against psoriasis

Bibliography

• Christophers E, Mrowietz U. In fitzpatrick's dermatology in general medicine. New York: McGraw-Hill, 2003
   Google Scholar
• Capalani E, Barker JNWN. The clinical genetics of psoriasis. Curr Genomics 2005;6:51-60
   Google Scholar
• Williams RC, Mckenzie AW, Roger JH, Joycey VC. HLA antigens in patients with guttate psoriasis. Br J Dermatol 1976;95:163-7
   PubMedGoogle Scholar
• Julien D, Baker JN. Genetics of psoriasis. J Eur Acad Dermatol Venereol 2006;20(S2):42-51
   Google Scholar
• Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes Immun 2007;8:1-12
   PubMed Web of Science ®Google Scholar
• Lomholt G. Psoriasis: prevalence, spontaneous course and genetics. Copenhagen: G.E.C. Gad, 1963
   Google Scholar
• Hellgren I. The prevalence in sex, age and occupational groups in total populations in Sweden: morphology, inheritance and association with other skin and rheumatic diseases. Stockholm: Almquist and Wiksell, 1967
   Google Scholar
• Bos JD, De Rei MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999;20:40-6
   PubMedGoogle Scholar
• Ajib R, Janbazian L, Rahal E, et al. HLA associations and v-beta T-lymphocyte expansions in patients with psoriasis, harboring toxin-producing Staphylococcus aureus. J Biomed Biotechnol 2005;4:310-5
   Google Scholar
• Nair RP, Duffin KC, Helms C, et al. Genome -wide scan reveals association of psoriasis with IL-23 and NF-kB pathways. Nat Genet 2009 In press, DOI: 10.1038/ng.311
   Google Scholar
• De Cid R, Riveira-Munoz E, Zeeuwen PLJM, et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009;41:211-5
   PubMed Web of Science ®Google Scholar
• Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974;109:207-11
   PubMed Web of Science ®Google Scholar
• Brandrup F, Holm N, Grunnet N, et al. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 1982;62:229-36
   PubMed Web of Science ®Google Scholar
• Naldi L, Parazzini F, Brevi A, et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992;127:212-7
   PubMed Web of Science ®Google Scholar
• Feldman SR, Clarck AR. Psoriasis. Med Clin North Am 1998;82:1135-43
   PubMedGoogle Scholar
• Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999;140(Suppl 54):1-7
   PubMed Web of Science ®Google Scholar
• Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990;136:1053-10
   PubMed Web of Science ®Google Scholar
• Picker LJ, Kishimoto TK, Smith CW, et al. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature 1991;349:796-9
   PubMed Web of Science ®Google Scholar
• Iijima W, Ohtani H, Nakayama T, et al. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules. A potential self-recruiting mechanism. Am J Pathol 2003;163:261-8
   PubMedGoogle Scholar
• Iwakura Y, Ishigame H. The IL-23/17 axis in inflammation. J Clin Invest 2006;116:1218-22
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Liotta F, et al. The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol 2008; published online doi: 10.1093/intimm/dxn 106
   PubMedGoogle Scholar
• Ai L-S, Lee S-F, Chen SSL, Liao F. Molecular characterization of CCR6: involvement of multi-domains in ligand binding and receptor signaling. J Biomed Sci 2004;11:818-28
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lowes M, Kikuchi T, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 cells. J Invest Dermatol 2008;128:1064-7
   PubMed Web of Science ®Google Scholar
• Jasny E, Eisenblatter M, Matz-Rensing K, et al. IL-12 impaired and IL-12-secreting dendritic cells produce IL-23 upon CD154 restimulation. J Immunol 2008;180:6629-39
   PubMed Web of Science ®Google Scholar
• Kanda N, Watanabe S. IL-12, IL-23, and IL-27 enhance human β-defensin-2 production in human keratinocytes. Eur J Immunol 2008;38:1287-96
   PubMedGoogle Scholar
• Lee MR, Cooper AJ. Immunopathogenesis of psoriasis. Aust J Dermatol 2006;47:151-9
   Google Scholar
• Imhof BA, Aurrand-Lions M. Angiogenesis and inflammation face off. Nat Med 2006;12:171-2
   PubMed Web of Science ®Google Scholar
• Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther Clin Risk Manag 2008;4:345-51
   PubMedGoogle Scholar
• Mease P. Influximab (Remicade) in the treatment of psoriatic arthritis. Ther Clin Risk Manag 2006;2:389-400
   PubMedGoogle Scholar
• Bartlett BL, Moody MN, Tyring SK. IL-12/23 inhibitors: the advantages and disadvantages of this novel approach for the treatment of psoriasis. Skin Ther Lett 2008;13:1-4
   PubMedGoogle Scholar
• Wu JJ. Interleukin-12, Iinterleukin-23, and psoriasis. J Am Acad Dermatol 2008;58:1083
   PubMedGoogle Scholar
• Mechcatie E. Ustekinumab approval delayed by FDA (News). Skin and Allergy News Feb. 2009. Available from: http://www.accessmylibrary.com/coms2/summary_0286-36865177_ITM
   Google Scholar
• Isotechnica, Randomized Placebo-Controlled Study of ISA247 in Plaque Psoriasis (SPIRIT), clinicaltrials.gov, no. NCT00244842; 2008
   Google Scholar
• Papp K, Bissonette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomized, multicentre, double-blind placebo-controlled phase III study. Lancet 2008;371:1337-42
   PubMed Web of Science ®Google Scholar
• Moldovan M-C, Sabbagh L, Breton G, et al. Triggering of T cell activation via CD4 dimers. J Immunol 2006;176:5438-45
   PubMedGoogle Scholar
• Pipex, Pipex Pharmaceuticals Announces Issuance Of Additional US Patent Covering CD4 Inhibitor Molecules. 802-2 US7345020; 2008
   Google Scholar
• Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58
   PubMed Web of Science ®Google Scholar
• Green NJ, Xiang J, Chen J, et al. Structure-activity studies of a series of dipyrazolo [3, 4-b: 3′, 4′ –d] pyridine-3-ones binding to the immune regulatory protein B7.1. Bioorg Med Chem 2003;11:2991-3013
   PubMedGoogle Scholar
• Pettersson LOG, Thrige DDG, Matthews IR, et al. Pyrazoloquinolines with immunomodulating activity. EP1813616A2; 2007
   Google Scholar
• Glick GD, Opipari AW. Compositions and methods related to novel compounds and targets thereof. USP class 7186712; 2007
   Google Scholar
• Blatt NB, Boitano AE, Lyssiotis CA, et al. Bz-423 superoxide signals apoptosis via selective activation of JNK, Bak, and Bax. Free Radic Biol Med 2008;45:1232-42
   PubMedGoogle Scholar
• Bhagavathula N, Nerusu KC, Hanosh A, et al. 7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2ylmethyl)-4, 5-didro-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423), a benzodiazepine, suppresses keratinocyte proliferation and has antipsoriatic activity in the human skin-severe, combined immunodeficient mouse transplant model. J Pharmacol Exp Ther 2008;324:938-47
   PubMed Web of Science ®Google Scholar
• Bell S. Use of Pirlindole for the treatment of diseases which are characterized by proliferation of T-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis. WO2006048242; EP1807083A2; 2007
   Google Scholar
• Bruhwyler J, Liegeois JF, Geczy J. Pirindole: A selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties. Pharmacol Res 1997;36:23-33
   PubMed Web of Science ®Google Scholar
• Colmegna I, Sainz B, Garry RF, et al. The proteasome and its implications in rheumatology. J Rheumatol 2005;32:1192-8
   PubMedGoogle Scholar
• Chumakov I, Guerassimenko O. UBP8RP polypeptides and their use in the treatment of psoriasis. EP1660651A2; 2006, WO2005024011A2; 2005, WO2005024011A3; 2005
   Google Scholar
• Naviglio S, Mattecucci C, Matoskova B, et al. UBPY: a growth-regulated human ubiquitin isopeptidase. EMBO J 1998;17:3241-50
   PubMedGoogle Scholar
• Ohteki T. Critical role for IL 15 in innate immunity. Curr Mol Med 2002;2:371-80
   PubMedGoogle Scholar
• Bulfone-Paus S, Ruckert R. Method of treating psoriasis with IL-15 antagonist. WO2001002003; 2001
   Google Scholar
• Farber EM, Cohen EN, Trozak DJ, Wilkinson DI. Peptide T improves psoriasis when infused into lesions in nanogram amounts. J Am Acad Dermatol 1991;25:658-64
   PubMedGoogle Scholar
• Johanssen O, Hiliges M, Talme T, et al. Speculations around the mechanism behind the action of peptide T in the healing of psoriasis. Acta Derm Venereol 1993;73:401-3
   PubMedGoogle Scholar
• Redwine LS, Pert CB, Rone JD, et al. Peptide T blocks GP120/CCR5 chemokine receptor-mediated chemotaxis. Clin Immunol 1999;93:124-31
   PubMedGoogle Scholar
• Baroni A, Paoletti I, Greco R, et al. Immunomodulatory effects of a set of amygdalin analogues on human keratinocyte cells. Exp Dermatol 2005;14:854-9
   PubMedGoogle Scholar
• Perez-Gonzalez JJ, Llebaria-Soldevilla A, Lagunas-Arnal C, Fernandez-Garcia A. Use of amygdalin analogues for the treatment of psoriasis. WO2006058940; 2006, EP1847270A1; 2007
   Google Scholar
• Araya E, Rodriguez A, Rubio J, et al. Synthesis and evaluation of diverse analogs of amygdalin as potencial peptidomimetics peptide T. Bioorg Med Chem Lett 2005;15:1493-6
   PubMedGoogle Scholar
• Yang HY, Chang HK, Lee JW, et al. Amygdallin suppresses lipopolysaccharide-induced expression of cycloxygenase 2 and inducible nitric oxide synthetase in mouse BV2 microglial cells. Neurol Res 2007;29(Suppl 1):S59-S64
   PubMed Web of Science ®Google Scholar
• Ramanthan R, Ghosal A, Miller MW, et al. Piperazine derivatives useful as CCR5 antagonists. EP1632479A2; J2006, WO2007050375; 2007
   Google Scholar
• Tagat JR, Steensma RW, Mccombie SW, et al. Piperazine based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2, 4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4[3(S)-methyl-4-[1(S)-[4-(trifluromethyl)phenyl]ethyl]-1-piperazinyl]-piperidine N1 oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. J Med Chem 2001;44:3343-6
   PubMed Web of Science ®Google Scholar
• Bondinell WE, Reader VA, Ku T, Wen FU. Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents. WO1998030218; 1998
   Google Scholar
• Jackson JK, Burt HM. Use of fucans in the treatment of psoriasis. EP1870105A1; 2007
   Google Scholar
• Shimaoka M, Ikeda M, Iida T, et al. Fucoidin, a potent inhibitor of leukocyte rolling, prevents neutrophil influx into phorbol-ester-induced inflammatory sites in rabbit lungs. Am J Respir Crit Care Med 1996;153:307-11
   PubMed Web of Science ®Google Scholar
• Schon MP, Drewniok C, Boehncke WH. Targeting selectin functions in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:163-8
   PubMedGoogle Scholar
• Meisner LF. Topical composition for the treatment of psoriasis and related skin disorders. US6440465; 2002
   Google Scholar
• McCarry MF. Glucosamine for psoriasis? Med Hypothesis 1996;48:437-41
   Google Scholar
• Hussain I, Kitigaki K, Businga TR, Kline JN. Expression of cysteinyl leukotriene receptor-1 in skin. J Am Acad Dermatol 2004;51:1032-3
   PubMedGoogle Scholar
• Mommers JM, Van Rossum MM, Kooijmans-Otero ME, et al. A novel LTB4 antagonist is not effective in the prevention of relapse in psoriasis. Br J Dermatol 2000;142:259-66
   PubMed Web of Science ®Google Scholar
• Eggler JF, Masamune H. Substituted chromans in the treatment of asthma, arthritis and related diseases. EP0391625A1; 1990
   Google Scholar
• Verma-Ashwani K, Malhotra S. Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors. EP1834953A1; 2007
   Google Scholar
• Rittinghausen R. Use of compositions containing petasites for treating diseases. WO2003088985; 2003, EP1803462A2; 2007
   Google Scholar
• Thomet OA, Wiessmann UN, Schapowal A, et al. Role of petasin in the potential anti-inflammatory activity of a plant extract of petasites hybridus. Biochem Pharmacol 2001;61:1041-7
   PubMed Web of Science ®Google Scholar
• Habeeb AG, Praveen-Rao PN, Knaus EE. Design and síntesis of 4,5-diphenyl-4-oxazolines: novel inhibitors of cycloxygenase-2 with analgesic and anti-inflammatory activity. J Med Chem 2001;44:2921-7
   PubMedGoogle Scholar
• Balachandran S, Gupta N, Muthukaman N, et al. Isoxazolines and their use as inhibitors of phosphodiesterase type-IV. EP20070105020; 2007, WO2008035315; 2008
   Google Scholar
• Dent G, Giembycz MA. Phosphodiester inhibitors: the Pink's medicinal compound for asthma? Thorax 1996;51:647-9
   PubMedGoogle Scholar
• Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18
   PubMed Web of Science ®Google Scholar
• Heidenreich R, Rocken M, Ghoreschi K. Angiogenesis: the new potential target for the therapy of psoriasis? Drug News Perspect 2008;21:97-105
   PubMed Web of Science ®Google Scholar
• De Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-91
   PubMed Web of Science ®Google Scholar
• Thomas AP, Johnstone C, Clayton E, et al. Quinazoline derivatives and pharmaceutical compositions containing them. US6897210; 2005
   Google Scholar
• Kane JL, Hirth BH, Yee C, et al. Novel new molecules with selective cytotoxicity against human microvascular endothelial cell proliferation. USPTO 20070254894- Class 514253060; 2006
   Google Scholar
• Arbiser J. Carbazole formulations for the treatment of psoriasis and angiogenesis. EP1896035A2; 2008
   Google Scholar
• Arbiser JL, Govindarajan B, Battle TE, et al. Carbazole is a naturally occuring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol 2006;126:1396-402
   PubMed Web of Science ®Google Scholar
• Pelicci PG, Chimenti S, Costanzo A, et al. Topical use of valproic acid for the prevention or treatment of psoriasis and acne. EP20040740209; 2008
   Google Scholar
• Michaelis M, Michaelis UR, Fleming I, et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004;65:520-7
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734-41
   PubMed Web of Science ®Google Scholar
• Lu X, Li Z, Xie A, et al. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity. US7244751; 2007
   Google Scholar
• Cuevas-Sanchez P, Romero-Garrido A. Use of 2, 5-dihydroxybenzenesulfonic acid in the production of medications for the treatment of angiodependent diseases such as cancer and psoriasis. EP1719509A1; 2006
   Google Scholar
• Kim MH. Flavonoids inhibit VEGF/BFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J Cell Biochem 2003;89:529-38
   PubMed Web of Science ®Google Scholar
• Shoab SS, Scurr JH, Coleridge-smith PD. Plasma VEGF as a marker of therapy in patients with chronic disease treated with oral micronized flavonoid fraction- a pilot study. Eur J Vasc Endovasc Surg 1999;18:334-8
   PubMedGoogle Scholar
• Lahey TP, Rajadhyasksha VJ. Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto. US6774142; 2004
   Google Scholar
• Czarnik AW. Deutriu-enrich Temsirolimus. IPC8 Class: AA61K31436FI USPC Class: 514291; (date not available)
   Google Scholar
• Rini B, Kar S, Kirkpatrick P. Temsirolimus. Nat Drug Discov 2007;6:599-600
   Google Scholar
• Meth MJ, Weinberg JM. Cyclopamine: inhibiting hedgehog in the treatment of psoriasis. Cutis 2006;78:185-8
   PubMedGoogle Scholar
• Tas S, Avci O. Rapid clearance of psoriatic lesions induced by topical cyclopamine. Dermatol 2004;209:126-31
   PubMedGoogle Scholar
• Endo H, Momota A, Oikawa A, Shinkai H. Psoriatic skin expresses the transcription factor Gii1: possible contribution of decreased neurofibromin expression. Br J Dermatol 2005;154:619-23
   Google Scholar
• Gudjonnsson JE, Aphale A, Grachtchouk M, et al. Lack of evidence for activation of the hedgehog pathway in psoriasis. J Invest Dermatol 2009;129:635-40
   PubMedGoogle Scholar
• Tas S, Avci O. Use of cyclopamine in the treatment of psoriasis and other skin disorders. EP1496895A1; 2005, WO2003088964; 2003
   Google Scholar
• Escobedo J, Pavco P, Sandburg J, et al. A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor. EP1767632A2; 2007
   Google Scholar
• Faria M, Ulrich H. The use of synthetic oligonucleotides as protein inhibitors and anti code drugs in cancer therapy: accomplishments and limitations. Curr Cancer Drug Target 2002;2:355-68
   PubMedGoogle Scholar
• Karadogan I, Akca S, Undar L. Resolution of psoriatic lesions with fludarabine. Am J Med 1999;107:300-1
   PubMed Web of Science ®Google Scholar
• Jordan J, Mey U, Bieber T, Wilsmann-Theis D. Paradoxical exacerbation of psoriasis during therapy with fludarabine. Eur J Dermatol 2008;18:365-6
   PubMedGoogle Scholar
• Kirkin RA, Erwin RA, Taub D, et al. Tyrphostin AG 490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen activated human cells. J Leukoc Biol 1999;65:891-9
   PubMedGoogle Scholar
• Stepkowsld SM, Kao J, Wang ME, et al. The mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol 2005;175:4236-46
   PubMedGoogle Scholar
• Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor. Science 2003;302:875-8
   PubMed Web of Science ®Google Scholar
• Brown GR, Bamford AM, Bowyer J, et al. Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett 2000;10:575-9
   PubMed Web of Science ®Google Scholar
• Badger AM, Bradbeer JN, Votta B, et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996;279:1453-61
   PubMed Web of Science ®Google Scholar
• Mortellaro A, Songia S, Gnocchi P, et al. New immunosuppressive drug PNU156804 blocks IL 2-dependent proliferation and NF-kB and AP-1 activation. J Immunol 1999;162:7102-9
   PubMed Web of Science ®Google Scholar
• Bianchi M, Bloom O, Raabe T, et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med 1996;183:927-36
   PubMed Web of Science ®Google Scholar
• Rosenberg EW, Noah PW, Skinner RB. Microorganisms and psoriasis. J Natl Med Assoc 1994;86:305-10
   PubMedGoogle Scholar
• Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 2007;12(1-2):80-7
   PubMed Web of Science ®Google Scholar
• Pandey S, Agrawal DK. Immunobiology of Toll-like receptors: emerging trends. Immunol Cell Biol 2006;84(4):333-41
   PubMed Web of Science ®Google Scholar
• Gearing AJ. Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol Cell Biol 2007;85(6):490-4
   PubMed Web of Science ®Google Scholar
• Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007;19(1):3-10
   PubMed Web of Science ®Google Scholar
• Gillet M, Conrad C, Geiges M, et al. Psoriasis triggered by Toll-Like Receptor agonist imiquimod in the presence of dermal plasmatoid dendritic cell precursors. Arch Dermatol 2004;140:1490-5
   PubMedGoogle Scholar
• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552-9
   PubMed Web of Science ®Google Scholar
• Gillet M, Nestle FO. Type I interferon blocking agents for prevention and treatment of psoriasis. EP1796722A1; 2007
   Google Scholar
• El-Ferizli J, Jenbazian L, Rubeiz N, et al. Streptococcus sp. and Staphylococcus aureus isolates from patients with psoriasis possess genes that code for toxins (super antigens): clinical and therapeutic implications. Immunopharmacol Immunotoxicol 2008;30:195-205
   PubMedGoogle Scholar
• Proft T, Frazer JD. Bacterial super antigens. Clin Exp Immunol 2003;133:299-306
   PubMed Web of Science ®Google Scholar
• Keino H, Watanabe T, Sato Y, et al. Therapeutic effect of the potent IL-12/!L-23 inhibitor STA-5326 on autoimmune uveoretinitis. Arthritis Res Ther 2008;10:R122
   Web of Science ®Google Scholar
• Arnold R, Seifert M, Asadullah K, Volk HD. Crosstalk between keratinocytes and T-lymphocytes via Fas/Fas ligand interaction: Modulation by cytokines. J Immunol 1999;162:7140-7
   PubMedGoogle Scholar
• Sermadiras S, Dumas M, Joly-Berville R, et al. Expression of Bcl2 and Bax in cultured normal human keratinocytes and melanocytes: relationship to differentiation and melanogenesis. Br J Dermatol 1997;137:883-9
   PubMedGoogle Scholar
• Greaney A, Nahimana L, Lagopoulos A, et al. Fas agonist induces high levels of apoptosis in hematological malignancies. Leuk Res 2005;30:415-26
   PubMedGoogle Scholar
• Skommer J, Wlodkovic D, Matto M, et al. HA14-1, a small molecule Bcl2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B-cells. Leuk Res 2006;30:322-31
   PubMed Web of Science ®Google Scholar
• Fecteau S, Basadonna GP, Freitas A, et al. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat Immunol 2001;2:58-63
   PubMedGoogle Scholar
• Sawicka E, Dubois G, Jarai G, et al. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+ CD25+ T-regulatory cells and enhances their functional activity. J Immunol 2005;175:7973-80
   PubMed Web of Science ®Google Scholar